Current therapeutic strategies for invasive and metastatic bladder cancer

OncoTargets and Therapy

Volumn 4, Issue , 2011, Pages 97-113

  Vishnu, Prakash ^a   Mathew, Jacob ^a   Tan, Winston W ^a  

^a MAYO CLINIC   (United States)

Author keywords

Biologic therapy; Bladder cancer; Chemotherapy; Neoadjuvant; PI3kinase mTOR pathway

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERIBULIN; ERLOTINIB; EVEROLIMUS; GEMCITABINE; IRINOTECAN; IXABEPILONE; LAPATINIB; METHOTREXATE; PACLITAXEL; PAZOPANIB; PEMETREXED; PRALATREXATE; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VINBLASTINE; VINFLUNINE;

ANEMIA; ANOREXIA; BLADDER CANCER; BLEEDING; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CONSTIPATION; CYSTECTOMY; DOSAGE SCHEDULE COMPARISON; DRUG FATALITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; GENE EXPRESSION PROFILING; GRANULOCYTOPENIA; HUMAN; HYPERTENSION; LEUKOPENIA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN; REVIEW; SENSORY NEUROPATHY; SEPSIS; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

EID: 84865287448     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S22875     Document Type: Review

References (110)

1. Cancer Facts and Figures. American Cancer Society; 2010. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.pdf. Accessed March 31, 2011.
2. SEER Stat Fact Sheets: bladder. National Cancer Institute; 2010. http://seer.cancer.gov/statfacts/html/urinb.html. Accessed March 31, 2011.
3. Mostofi FK, Davis CJ, Sesterhenn IA. Pathology of Tumors of the Urinary Tract. Lyon, France: Saunders; 1988.
4. Shelley MD, Mason MD, Kynaston H. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev. 2010;36(3):195-205.
5. Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol. 2002;167(4): 1573-1583.
6. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Biology and management of bladder cancer. N Engl J Med. 1990;322(16): 1129-1138.
7. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666-675.
8. Babaian RJ, Johnson DE, Llamas L, Ayala AG. Metastases from transitional cell carcinoma of urinary bladder. Urology. 1980;16(2): 142-144.
9. Leissner J, Hohenfellner R, Thuroff JW, Wolf HK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int. 2000;85(7):817-823.
10. AJCC Cancer Staging Manual. 7th ed. New York: springer; 2010.
11. Karl A, Carroll PR, Gschwend JE, et al. The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol. 2009;55(4):826-835.
12. Koppie TM, Vickers AJ, Vora K, Dalbagni G, Bochner BH. Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer. 2006;107(10):2368-2374.
13. Stein JP, Skinner DG. The role of lymphadenectomy in high-grade invasive bladder cancer. Urol Clin North Am. 2005;32(2):187-197.
14. Fleischmann A, Thalmann GN, Markwalder R, Studer UE. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J Clin Oncol. 2005;23(10):2358-2365.
15. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10(7):1066-1073.
16. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15(7):2564-2569.
17. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602-4608.
18. Lin CC, Hsu CH, Huang CY, et al. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens. Urology. 2007;69(3):479-484.
19. Karakiewicz PI, Shariat SF, Palapattu GS, et al. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol. 2006;50(6):1254-1260. discussion 1261-1252.
20. Bochner BH, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol. 2006;24(24):3967-3972.
21. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res. 2006;12(22):6663-6676.
22. Kuczyk MA, Bokemeyer C, Serth J, et al. p53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur J Cancer. 1995;31 A(13-14):2243-2247.
23. Tsuji M, Kojima K, Murakami Y, Kanayama H, Kagawa S. Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens. Br J Urol. 1997;79(3):367-372.
24. Lorenzo-Romero JG, Salinas-Sanchez AS, Gimenez-Bachs JM, et al. Prognostic implications of p53 gene mutations in bladder tumors. J Urol. 2003;169(2):492-499.
25. Sarkis AS, Bajorin DF, Reuter VE, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol. 1995;13(6):1384-1390.
26. Hussain SA, Ganesan R, Hiller L, et al. Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. Br J Cancer. 2003;88(4):586-592.
27. Cooke PW, James ND, Ganesan R, Burton A, Young LS, Wallace DM. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU Int. 2000;85(7):829-835.
28. Duggan B, Williamson K. Molecular markers for predicting recurrence, progression and outcomes of bladder cancer (do the poster boys need new posters?). Curr Opin Urol. 2004;14(5):277-286.
29. Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res. 2005;11(7):2625-2636.
30. Hoffmann AC, Wild P, Leicht C, et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia. 2010;12(8):628-636.
31. Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 2007;18(3):522-528.
32. Takara K, Tsujimoto M, Kokufu M, Ohnishi N, Yokoyama T. Up-regulation of MDR1 function and expression by cisplatin in LLCPK1 cells. Biol Pharm Bull. 2003;26(2):205-209.
33. Smith SC, Baras AS, Dancik G, et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol. 2011;12(2):137-143.
34. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997;158(1):62-67.
35. Teramukai S, Nishiyama H, Matsui Y, Ogawa O, Fukushima M. Evaluation for surrogacy of end points by using data from observational studies: tumor downstaging for evaluating neoadjuvant chemotherapy in invasive bladder cancer. Clin Cancer Res. 2006;12(1): 139-143.
36. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet. 1999;354(9178): 533-540.
37. Sherif A, Rintala E, Mestad O, et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer - Nordic cystectomy trial 2. Scand J Urol Nephrol. 2002;36(6):419-425.
38. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859-866.
39. Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: nordic cystectomy trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol. 1996;155(6):1903-1906.
40. Cortesi E. Neoadjuvant treatment for locally advanced bladder cancer: a randomized prospective clinical trial. American Society of Clinical Oncology Annual Meeting; 1995. Philadelphia, PA.
41. Vale CL; Meta-analysis Group MCTU, London, UK. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48(2):202-205; discussion 205-206.
42. Griffiths G, trialists. OboIco. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 Trial. J Clin Oncol. 2011. doi: 10.1200/JCO.2010.32.3139.
43. Herr HW, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004;22(14):2781-2789.
44. Scosyrev E, Ely BW, Messing EM, et al. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int. 2010. doi: 10.1111/j.1464-410X.2010.09900.x.
45. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068-3077.
46. Dash A, Pettus JA, Bochner BH, et al. Efficacy of neo-adjuvant gemcitabine plus cisplatin (GC) in muscle-invasive urothelial cancer (UC). American Society of Clinical Oncology Annual Meeting 2007; Chicago, IL.
47. Smith DC, Grivas P, Daignault S, et al. A phase II trial of neoadjuvant ABI-007, carboplatin, and gemcitabine (ACG) in patients with locally advanced carcinoma of the bladder. American Society of Clinical Oncology Genitourinary cancer symposium; 2011. Orlando, FL.
48. Blick C, Hall P, Pwint T, et al. Accelerated MVAC as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. American Society of Clinical Oncology Genitourinary Cancer Symposium; 2011. Orlando, FL, USA.
49. Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20(14):3061-3071.
50. Housset M, Dufour B, Durdux C, Chretien Y, Mejean A, Baillet F. Concurrent radio-chemotherapy in infiltrating cancer of the bladder: a new therapeutic approach? Cancer Radiother. 1998;2(Suppl 1): 67s-72s.
51. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998;16(11):3576-3583.
52. Kachnic LA, Kaufman DS, Heney NM, et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol. 1997;15(3):1022-1029.
53. Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol. 1998;16(4):1298-1301.
54. Sternberg CN, Pansadoro V, Calabro F, et al. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer. 2003;97(7):1644-1652.
55. DeVere White RW, Lara PN Jr, Goldman B, et al. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol. 2009;181(6):2476-2480. discussion 2480-2471.
56. Calabro F, Sternberg CN. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2009;55(2):348-358.
57. Vale CL, On behalf of Meta-analysis Group MCTU, London, UK. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005;48(2):189-199. discussion 199-201.
58. Cognetti F, Ruggeri EM, Felici A, et al. Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomized phase III trial. American Society of Clinical Oncology Annual Meeting; 2008. Chicago, IL.
59. Stadler WM, Lerner SP, Groshen S, et al. Randomized trial of p53 targeted adjuvant therapy for patients (pts) with organ- confined nodenegative urothelial bladder cancer (UBC). American Society of Clinical Oncology Annual Meeting; 2009. Chicago, IL.
60. Paz-Ares G, Solsona E, Esteban E, et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01study. American Society of Clinical Oncology Annual Meeting; 2010. Chicago, IL.
61. Meyers FJ, Palmer JM, Freiha FS, et al. The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: a northern california oncology group study. J Urol. 1985;134(6):1118-1121.
62. Oliver RT, England HR, Risdon RA, Blandy JP. Methotrexate in the treatment of metastatic and recurrent primary transitional cell carcinoma. J Urol. 1984;131(3):483-485.
63. Soloway MS, Einstein A, Corder MP, Bonney W, Prout GR Jr, Coombs J. A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Collaborative Group A Study. Cancer. 1983;52(5): 767-772.
64. Lorusso V, Pollera CF, Antimi M, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer. 1998;34(8):1208-1212.
65. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997;15(5):1853-1857.
66. Pronzato P, Vigani A, Pensa F, Vanoli M, Tani F, Vaira F. Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. Am J Clin Oncol. 1997;20(5):519-521.
67. Hillcoat BL, Raghavan D, Matthews J, et al. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol. 1989;7(6):706-709.
68. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 1989;64(12):2448-2458.
69. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990;8(6):1050-1055.
70. Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001;19(10): 2638-2646.
71. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006;42(1):50-54.
72. von der Maase H, Andersen L, Crino L, Weinknecht S, Dogliotti L. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol. 1999;10(12):1461-1465.
73. Adamo V, Magno C, Spitaleri G, et al. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen. Oncology. 2005;69(5): 391-398.
74. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/ cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy. American Society of Clinical Oncology Annual Meeting 2007; Chicago, IL.
75. Bamias A, Aravantinos G, Deliveliotis C, et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004;22(2):220-228.
76. Dogliotti L, Carteni G, Siena S, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007;52(1):134-141.
77. Dreicer R, Manola J, Roth BJ, et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer. 2004;100(8):1639-1645.
78. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatinbased chemotherapy: phase II - results of EORTC study 30986. J Clin Oncol. 2009;27(33):5634-5639.
79. Dreicer R, Li H, Cooney MM, Wilding G, Roth BJ. Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group. Cancer. 2008;112(12):2671-2675.
80. von der Maase H, Lehmann J, Gravis G, et al. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Ann Oncol. 2006;17(10): 1533-1538.
81. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914-923.
82. Quinn D I., Aparicio A, Tsao-Wei DD, et al. Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC) - Final report: a California Cancer Consortium-led NCI/CTEP-sponsored trial. American Society of Clinical Oncology Annual Meeting; 2010. Chicago, IL.
83. Mitra AP, Lin H, Datar RH, Cote RJ. Molecular biology of bladder cancer: prognostic and clinical implications. Clin Genitourin Cancer. 2006;5(1):67-77.
84. Hahn NM, Stadler WM, Zon R, et al. Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC). American Society of Clinical Oncology Annual Meeting; 2010. Chicago, IL.
85. Hussain M, Vaishampayan U, Du W, Redman B, Smith DC. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol. 2001;19(9):2527-2533.
86. Witte RS, Elson P, Bono B, et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol. 1997;15(2):589-593.
87. Meluch AA, Greco FA, Burris HA 3rd, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol. 2001;19(12):3018-3024.
88. Di Lorenzo G, Autorino R, Giordano A, et al. FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. Jpn J Clin Oncol. 2004;34(12):747-750.
89. Culine S, Rebillard X, Iborra F, et al. Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: a pilot study. Anticancer Res. 2003;23(2C):1903-1906.
90. Kruczynski A, Hill BT. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol. 2001;40(2):159-173.
91. Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454-4461.
92. Culine S, Theodore C, De Santis M, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinumcontaining regimen. Br J Cancer. 2006;94(10):1395-1401.
93. Vaughn DJ, Srinivas S, Stadler WM, et al. Vinflunine in platinumpretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer. 2009;115(18): 4110-4117.
94. Albers P, Park SI, Niegisch G, et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment (German Association of Urological Oncology (AUO) trial AB 20/99). Ann Oncol. 2011;22(2):288-294.
95. Sweeney CJ, Roth BJ, Kabbinavar FF, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006;24(21):3451-3457.
96. Toppmeyer DL, Goodin S. Ixabepilone, a new treatment option for metastatic breast cancer. Am J Clin Oncol. 2010;33(5):516-521.
97. Dreicer R, Li S, Manola J, Haas NB, Roth BJ, Wilding G. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer. 2007;110(4):759-763.
98. Wong Y, Litwin S, Plimack ER, et al. Effect of EGFR inhibition with cetuximab on the efficacy of paclitaxel in previously treated metastatic urothelial cancer. American Society of Clinical Oncology Genitourinary Cancers Symposium; 2011. Orlando, FL.
99. th Europenan Society of Medical Oncology Congress; 2010. Milan, Italy.
100. Availabe from: http://www.Clinicaltrials.gov.2010. Accessed March 31, 2011.
101. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World Health Organization Classification of Tumours. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2004:359.
102. Dahm P, Gschwend JE. Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur Urol. 2003;44(6):672-681.
103. Swanson DA, Liles A, Zagars GK. Preoperative irradiation and radical cystectomy for stages T2 and T3 squamous cell carcinoma of the bladder. J Urol. 1990;143(1):37-40.
104. Lughezzani G, Sun M, Jeldres C, et al. Adenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortality. Urology. 2010;75(2):376-381.
105. Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer. 2005;103(6):1172-1178.
106. Bex A, Nieuwenhuijzen JA, Kerst M, et al. Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer. Urology. 2005;65(2):295-299.
107. Spiess PE, Kassouf W, Steinberg JR, et al. Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol. 2007;25(1):38-45.
108. Russo P, Brady MS, Conlon K, et al. Adult urological sarcoma. J Urol. 1992;147(4):1032-1036; discussion 1036-1037.
109. Lopez-Beltran A, Pacelli A, Rothenberg HJ, et al. Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol. 1998;159(5):1497-1503.
110. Froehner M, Gaertner HJ, Manseck A, Wirth MP. Durable complete remission of metastatic sarcomatoid carcinoma of the bladder with cisplatin and gemcitabine in an 80-year-old man. Urology. 2001;58(5):799.